Afrim Iljazi1, Cenk Ayata2, Messoud Ashina1,3, Anders Hougaard4. 1. Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Nordre Ringvej 57, DK-2600, Glostrup, Denmark. 2. Stroke Service and Neuroscience Intensive Care Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. 3. Institute of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark. 4. Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Nordre Ringvej 57, DK-2600, Glostrup, Denmark. ahougaard@dadlnet.dk.
Abstract
PURPOSE OF REVIEW: Vasoactive peptides play a key role in the attack-initiating cascade of migraine. Recent studies have highlighted a potentially important role for endothelin-1, a potent vasoconstrictor peptide, in migraine pathophysiology. Here, we review the current data on endothelin's involvement in migraine. RECENT FINDINGS: We identified 23 articles. Nine studies reported on endothelin-1 plasma concentrations in patients with migraine, eight studies investigated relevant genetic associations, five studies investigated endothelin-1 and spreading depression in animals, and one randomized controlled clinical trial tested the efficacy of an endothelin antagonist in the acute treatment of migraine in patients both with and without aura. Elevated endothelin-1 plasma levels have been reported in the early phase of migraine attacks. Genetic abnormalities related to the endothelin type A receptor have been reported in migraineurs. Endothelin-1 potently induces spreading depression in animals, which may explain the connection between endothelial irritation and migraine aura. Endothelin-1 could be a primary factor in the attack-triggering cascade of migraine attacks with and without aura. Additional studies in humans and animal models are needed to further elucidate the role of endothelin-1 in migraine.
PURPOSE OF REVIEW: Vasoactive peptides play a key role in the attack-initiating cascade of migraine. Recent studies have highlighted a potentially important role for endothelin-1, a potent vasoconstrictor peptide, in migraine pathophysiology. Here, we review the current data on endothelin's involvement in migraine. RECENT FINDINGS: We identified 23 articles. Nine studies reported on endothelin-1 plasma concentrations in patients with migraine, eight studies investigated relevant genetic associations, five studies investigated endothelin-1 and spreading depression in animals, and one randomized controlled clinical trial tested the efficacy of an endothelin antagonist in the acute treatment of migraine in patients both with and without aura. Elevated endothelin-1 plasma levels have been reported in the early phase of migraine attacks. Genetic abnormalities related to the endothelin type A receptor have been reported in migraineurs. Endothelin-1 potently induces spreading depression in animals, which may explain the connection between endothelial irritation and migraine aura. Endothelin-1 could be a primary factor in the attack-triggering cascade of migraine attacks with and without aura. Additional studies in humans and animal models are needed to further elucidate the role of endothelin-1 in migraine.
Authors: Dixon Yang; Cen Zhang; Setareh S Omran; Brett Cucchiara; Tatjana Rundek; Clinton B Wright; Ralph L Sacco; Mitchell S V Elkind; Jose Gutierrez Journal: J Neurol Sci Date: 2021-11-26 Impact factor: 3.181
Authors: Anders Hougaard; Samaira Younis; Afrim Iljazi; Kristian A Haanes; Ulrich Lindberg; Mark B Vestergaard; Faisal M Amin; Kazutaka Sugimoto; Lars S Kruse; Cenk Ayata; Messoud Ashina Journal: J Cereb Blood Flow Metab Date: 2019-09-09 Impact factor: 6.200
Authors: Nicoletta Brunelli; Claudia Altamura; Carlo A Mallio; Gianguido Lo Vullo; Marilena Marcosano; Marcel Bach-Pages; Bruno Beomonte Zobel; Carlo Cosimo Quattrocchi; Fabrizio Vernieri Journal: Int J Environ Res Public Health Date: 2022-07-14 Impact factor: 4.614